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Available online 4 April 2016Low-density lipoprotein receptor-related protein-1 (LRP1) is a multifunctional uptake receptor for chylomicron
remnants in the liver. In vascular smooth muscle cells LRP1 controls reverse cholesterol transport through
platelet-derived growth factor receptor β (PDGFR-β) trafﬁcking and tyrosine kinase activity. Here we show
that LRP1 regulates hepatic energy homeostasis by integrating insulin signaling with lipid uptake and secretion.
Somatic inactivation of LRP1 in the liver (hLRP1KO) predisposes to diet-induced insulin resistance with dyslipid-
emia and non-alcoholic hepatic steatosis. On a high-fat diet, hLRP1KOmice develop a severeMetabolic Syndrome
secondary to hepatic insulin resistance, reduced expression of insulin receptors on thehepatocyte surface andde-
creased glucose transporter 2 (GLUT2) translocation. While LRP1 is also required for efﬁcient cell surface insulin
receptor expression in the absence of exogenous lipids, this latent state of insulin resistance is unmasked by ex-
posure to fatty acids. This further impairs insulin receptor trafﬁcking and results in increased hepatic lipogenesis,
impaired fatty acid oxidation and reduced very low density lipoprotein (VLDL) triglyceride secretion.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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PDGF1. Introduction
Low-density lipoprotein (LDL) receptor-related protein 1 (LRP1) is a
multifunctional transmembrane receptor with diverse biological prop-
erties that are essential for the maintenance of normal mammalian
physiology (Dieckmann et al., 2010). In the liver, LRP1 functions in con-
cert with the LDL receptor (LDLR) in the clearance of ApoE-containing
chylomicron remnants and very low density lipoprotein (VLDL) circu-
lating in plasma (Rohlmann et al., 1998), as well as a number of other
pro-atherogenic ligands (Espirito Santo et al., 2004). Hepatic LRP1 also
binds hepatic lipase and lipoprotein lipase (LPL) (Verges et al., 2004),
further contributing to the role of LRP1 in overall lipid homeostasis. In
addition to functioning as an uptake receptor, LRP1 regulateslar Genetics, UT Southwestern
eurodegeneration Research, UT
. Xian),
. This is an open access article underintracellular trafﬁcking of other cell surface receptors. In ﬁbroblasts
and smooth muscle cells, LRP1 controls platelet-derived growth factor
receptor β (PDGFRβ) trafﬁcking and tyrosine kinase activity, which in
turn regulates extracellular signal regulated kinase (Erk) activation
and cell proliferation. Thesemechanisms are fundamental to the protec-
tive role of LRP1 in atherogenesis and the protection of the vascularwall
(Boucher et al., 2003; Takayama et al., 2005; Zhou et al., 2009).
The importance of LRP1 in lipid homeostasis and atherosclerosis is
well established, however the role of LRP1 in glucose metabolism is
just beginning to be understood. In vitro proteomic studies demonstrate
that LRP1 functions as an integral component of glucose transporter
storage vesicles (GSV) and LRP1 depletion in adipocytes is associated
with decreased glucose transporter 4 (GLUT4) expression and decreased
insulin-induced glucose uptake (Jedrychowski et al., 2010). In addition
to regulating glucose uptake throughGLUT4, LRP1 itself can be regulated
by insulin signaling. In both adipocytes and hepatocytes, insulin stimu-
lates a rapid translocation of LRP1 to the cell surface, leading to increased
uptake of postprandial lipoproteins (Descamps et al., 1993; Laatsch et al.,
2009). Moreover, a central role for LRP1 in overall energy metabolism is
further suggested by a mouse model of induced LRP1 deﬁciency in thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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leading to accelerated weight gain and obesity, decreased energy con-
sumption, and increased food intake (Liu et al., 2011).
Recently, the LIPGENE study has identiﬁed rs4759277 in the Lrp1
gene as one of the top single nucleotide polymorphisms (SNPs) associ-
ated with fasting insulin levels and insulin resistance in patients with
Metabolic Syndrome (Delgado-lista et al., 2014). Insulin resistance and
dyslipidemia, in addition to central obesity, are key features of theMet-
abolic Syndrome. As a clinical entity, the prevalence of Metabolic Syn-
drome worldwide is increasing, largely related to rising rates of
obesity and sedentary lifestyles (Grundy et al., 2005). The relationship
between the hallmarks of theMetabolic Syndrome, in particular insulin
resistance and dyslipidemia, is not well understood. However, it has
been proposed that Metabolic Syndrome in general is mediated by an
underlying insulin resistance (Grundy et al., 2004).
To explore the impact of LRP1 on insulin resistance and theMetabol-
ic Syndrome, we generated a novel genetic model of diet-induced he-
patic insulin resistance based on hepatic LRP1 deﬁciency. We found
that liver-speciﬁc LRP1 knockout (hLRP1KO) mice when maintained
on a standard chow diet exhibit mild dyslipidemia and impaired insulin
signaling, however, when challenged with a high-fat diet (HFD) they
rapidly develop obesity, marked insulin resistance, hyperglycemia, and
hepatic steatosis. Collectively, these data suggest that hepatic LRP1 is es-
sential for modulating hepatic insulin action and highlight a pivotal
mechanism in the development of Metabolic Syndrome.
2. Materials and Methods
2.1. Materials
Human insulin was purchased from Humalog. The anti-phospho-
insulin receptor (pIR), anti-IR, anti-protein kinase B (AKT), anti-pAKT,
anti-β-actin, anti-glycogen synthase kinase (GSK) 3β, anti-pGSK3β
and anti-calnexin antibodies were purchased from Cell Signaling. Anti-
GLUT2 and anti-GLUT4 antibodies were purchased from Millipore.
Anti-apolipoprotein B (apoB) and anti-apoE antibodies were purchased
from Calbiochem. Generation of antibodies to LDLR, LRP1 and apoAI
have been described previously (Ishibashi et al., 1993; Rohlmann
et al., 1998). Peroxidase-labeled anti-rabbit or mouse IgG was from
GH Healthcare and Peroxidase-labeled anti-goat IgG was from Santa
Cruz. ECL system was from Thermo Scientiﬁc.
2.2. Mouse Experiments
Lrp1ﬂox/ﬂoxmicewere generated as previously described (Rohlmann
et al., 1998; Rohlmann et al., 1996), and maintained on a mixed C57BL/
6x 129SvJ strain background. Albumin-Cre mice on a congenic C57BL/6
background were from Jackson Laboratory (Stock number 003574).
Lrp1ﬂox/ﬂox mice were crossed with albumin-Cre; Lrp1ﬂox/ﬂox mice to
generate hLRP1KO and hLRP1+/+ littermates (WT) by brother-sister
mating. Animals were housed in speciﬁc pathogen-free facilities with
12-hour light/12-hour dark cycle. Animals were fed either a normal
chow diet (Teklad 18%, Harlan) or a HFD containing 60% fat (D12492,
Research Diets) ad libitum with free access to water. All experimental
protocols were approved by the Institutional Animal Care andUse Com-
mittees of the University of Texas Southwestern Medical Center. Unless
speciﬁcally mentioned, all experiments were performed on WT and
hLRP1KO mice fed with chow or HFD for 16 weeks.
2.3. Glucose and Insulin Tolerance Tests
Glucose, insulin and pyruvate tolerance tests were performed
16 weeks after chow diet or HFD feeding; glucose tolerance test
(1 g glucose/kg of body weight, after overnight fasting), insulin toler-
ance test (1 unit human regular insulin/kg body weight, after 6 h of
fasting), and pyruvate tolerance test (1 g pyruvate/kg of body weight,after overnight fasting). Blood samples were obtained by tail bleeding
and analyzed for glucose content (Contour brand glucometer) immedi-
ately before and at time points of 0, 30, 60, 90 and 120 min after an in-
traperitoneal injection.
2.4. Hyperinsulinemic Euglycemic Clamp
Anesthesia was accomplished by 2% isoﬂuorane. For clamps, silicone
catheters were aseptically placed in the jugular vein. Rimadyl (5mg/kg,
sc) was administered for pain control and animals were allowed to re-
cover (4–5 days) to achieve preoperative weight prior to experiments.
Clamps were performed in conscious unrestrained animals as previous-
ly described (Xia et al., 2015). Clamps were initiated by primed contin-
uous infusion of insulin (3 mU/kg/min) and glucose was maintained
constant at ~130 mg/dL during the clamped state.
2.5. In Vivo Insulin Stimulation
Following an overnight fast, mice were injected with 0.9% NaCl or 1
unit of regular human insulin/kg (Humalog) intraperitoneally. 5 min
after injection of the insulin bolus, livers were rapidly removed and fro-
zen in liquid nitrogen.
2.6. Primary Hepatocytes
Mouse primary hepatocytes were isolated from 8- to 10-week-old
mice by collagenase perfusion as described previously (Wang et al.,
2012). Cells were cultured in the presence of 1000 mg/L glucose and
starved for overnight, following by 24-hour treatment with 0.25 mM
albumin-bound Palmitate or 0.5% BSA. Insulin (100 nM/L) or 0.9%
NaCl was added to the culture medium for 2 min.
2.7. Surface Protein Biotinylation
Primary mouse hepatocytes were grown in 6-well culture dishes
and cell surface proteins were biotinylated as previously described
(Chen et al., 2010). After insulin treatment, hepatocytes were washed
with cold PBS buffer and then incubated in PBS buffer containing
1.0 mg/ml sulfo-NHS-SS-biotin (Pierce) for 30 min at 4 °C. Excess re-
agent was quenched by rinsing in cold PBS containing 100 mM glycine.
Cell lysateswere prepared in 160 μl of RIPA lysis buffer [50mMTris-HCl,
150mMNaCl, 1% NP-40, 2 mMEDTA, 2 mMMgCl2, and protease inhib-
itor mixture (Sigma), (pH8.0)]. After 20 min incubated at 4 °C, lysates
were collected and centrifuged at 14,000 × rpm for 10 min. 100 μg of
total proteins were incubated with 100 μl of NeutrAvidin agarose
(Pierce) at 4 °C for 1.5 h. Agarose pellets were washed three times
using washing buffer [500 mM NaCl, 150 mM Tris-HCl, 0.5% Triton X-
100 (pH8.0)], biotinylated surface proteins were eluted from agarose
beads by boiling in 2x SDS sample loading buffer. Protein were separat-
ed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), transferred to nitrocellulose, and blotted with different
antibodies.
2.8. Western Blot Analysis
Protein samples from liver tissues or hepatocytes were separated by
SDS-PAGE and transferred onto nitrocellulose membranes (Bio-Rad).
Blots were probed separately with antibodies as indicated in ﬁgures.
After incubation with horseradish-peroxidase-conjugated secondary
antibodies, membranes were visualized with SuperSignal West Pico
Chemiluminescence reagents on X-ray ﬁlms. When comparing phos-
phorylated and total IR and AKT protein, the samemembranes incubat-
ed with phospho-antibodies were stripped and reprobed with non-
phospho-antibodies. Band intensity was quantiﬁed using scanning den-
sitometry of the autoradiogram with NIH Image J software (http://rsb.
info.nih.gov/ij/).
137Y. Ding et al. / EBioMedicine 7 (2016) 135–1452.9. Plasma and Liver Biological Parameter Analysis
After an overnight fast, animals were anesthetized with isoﬂurane
and blood was collected. Total triglyceride (TG) and cholesterol were
determined using a commercial kit (Inﬁnity Triglyceride/Cholesterol
Reagents, Thermo Scientiﬁc), and non-esteriﬁed fatty acid (NEFA) was
assayed using commercial kits (Wako, Richmond, VA). Plasma from
overnight-fasted mice was subjected to fast-performance liquid chro-
matography (FPLC) to assess the distribution of lipids within the lipo-
protein fractions as described previously (Biddinger et al., 2008). For
apolipoprotein analysis, equal volumes of whole plasma or pool of
equal aliquots of three consecutive FPLC fractionswere subjected to im-
munoblottingwith apoB, apoE and apoAI antibodies. Plasma insulinwas
measured by using high sensitive mouse insulin enzyme-linked immu-
nosorbent assay (ELISA) kit (Crystal Chem Inc.). Whole blood glucose
was measured by blood glucose monitor (Contour). Hepatic lipids
were extracted by homogenization of liver tissue (~100 mg) in
chloroform:methanol at 2:1 by volume and analyzed as described
(Ding et al., 2011).
2.10. VLDL Secretion Studies
Tomeasure the VLDL-TG secretion rate, micewere fasted for 6 h, pre
bled by retro orbital bleeding, and injected intravenously with 10%
tyloxapol (Triton WR-1339; T-8761; Sigma-Aldrich, St. Louis, MO;
500 mg/kg body weight) to inhibit lipolysis. Plasma samples were
drawn serially 0, 30, 60, 90 and 120 min after injection. Plasma TG
from each time was measured by plate assay using Inﬁnity TG Reagent
(Thermo Scientiﬁc).
2.11. Histological Analysis
Livers were ﬁxed by immersion in neutral buffered PFA (4%), and
then transferred to OCT reagent for snap-freezing. 8-μm sections were
stained with haematoxylin & eosin (H&E) or Oil O Red staining. Slides
were analyzed using Zeiss Axiophot microscope and images captured
with a SPOT digital camera.
2.12. Analysis of Gene Expression by Quantitative RT-PCR
Total RNAwas isolated usingRNeasy kit (Qiagen). Twomicrogramof
RNAwas reverse transcribed using randomhexamer primers (Life tech-
nologies), and cDNA was diluted 1:20 and used for quantitative PCR
employing gene-speciﬁc primers and SYBR Green reactionmix. Fluores-
cence was monitored and analyzed in an ABI prism 7900HT sequence
detection system (Applied Biosystems). Each sample was measured in
triplicate and the levels of each target mRNA were normalized to the
levels of cyclophilin. Sequences of the primers used for real-time PCR
were listed in Table S1.
2.13. Statistical Analysis
All datawere expressed asmean±SEM. Unpaired 2-tailed student's
t test or two-way ANOVA testwere used for statistical analysis. A P value
of less than 0.05 between two groups was considered signiﬁcant.
3. Results
3.1. Hepatic Inactivation of LRP1 in Mice Promotes Diet-induced Obesity
Hepatic LRP1 is essential for the uptake of chylomicron remnants by
hepatocytes (Rohlmann et al., 1998). To investigate the effect of HFD in
the setting of hepatic LRP1 deﬁciency, hLRP1KOmicewere generated by
breeding Lrp1ﬂox/ﬂox mice with albumin-Cre transgenic mice to yield
hLRP1KO mice on a mixed C57BL/6x129SvJ background, as previously
described (Basford et al., 2011; Rohlmann et al., 1996). Immunoblotanalysis conﬁrmed the deletion of LRP1 protein in liver from hLRP1KO
mice, whereas LRP1 was preserved in the brain, white adipose tissue
(WAT), and skeletal muscle (Fig. 1a). Eight-week-old male hLRP1KO
mice and their littermate controls (Lrp1ﬂox/ﬂox, orWT)weremaintained
on chow diet or HFD for 16 weeks. There was no difference in body
weight between hLRP1KO and WT mice on chow diets. HFD resulted
in increased body and fat mass in both WT and hLRP1KO mice, with
hLRP1KO mice demonstrating signiﬁcantly accelerated body weight
gain starting at 14 weeks of age, leading to a 24.6% (50.98 ± 1.38 vs.
40.92 ± 1.47, P b 0.01) higher body weight when compared with WT
mice at the end of the experiment. The dramatic weight gainwas attrib-
uted entirely to an increase in body fat content and percent body fat
(Fig. 1b and 1c).Metabolicmeasurements performed over a 5-daymon-
itoring period showed no differences in daily food intake, O2 consump-
tion, CO2 production, and total energy expenditure between WT and
hLRP1KO mice on HFD (Fig. S1).
3.2. Liver LRP1Deﬁciency Impairs Insulin Sensitivity and Aggravates Insulin
Resistance in HFD-fed Mice
Obesity and increased adipocyte mass were suggestive of insulin re-
sistance, as insulin is a key regulator in glucose and lipid metabolism.
Therefore, we next investigated whether hLRP1 deﬁciency affected glu-
cose homeostasis and insulin action. Although glucose and insulin con-
centrations in fasting plasma were not signiﬁcantly different between
WT and hLRP1KOmice on chow diet, HFD resulted in 73.9% higher plas-
ma glucose (184.3 ± 16.02 vs. 106± 5.32, P b 0.01) and 60 % higher in-
sulin (5.28 ± 0.37 vs. 3.3 ± 0.36, P b 0.01) levels in hLRP1KOmice than
that observed inWTcontrols (Fig. 2a). To determinewhole-body insulin
sensitivity, we performed oral glucose tolerance tests (GTT), intraperi-
toneal insulin tolerance tests (ITT) and pyruvate tolerance tests (PTT)
after dietary intervention for 16 weeks. Comparison of chow-fed WT
and hLRP1KO mice demonstrated that these animals exhibited similar
glucose tolerance, pyruvate tolerance and insulin sensitivity (Fig. 2b,
2c and 2d). In contrast, when compared with HFD-fed WT mice, the
HFD-fed hLRP1KOmice displayed impaired glucose tolerance and pyru-
vate tolerance, associated with reduced insulin sensitivity (P b 0.01,
Area Under Curve (AUC)), highlighting a loss of glycemic control.
To discern whether LRP1 deﬁciency or obesity was the primary trig-
ger of impaired insulin action, we performed hyperinsulinemia-
euglycemic clamp studies in 4-week HFD-fed mice, prior to any signiﬁ-
cant divergence in body weight (Fig. S2a). The glucose infusion rate re-
quired to maintain euglycemia trended lower in hLRP1KO mice
(Fig. S2b), however, no changes in whole-body glucose turnover were
apparent (Fig. S2c). Although endogenous glucose production was un-
changed in the basal state (Fig. S2d, left panel), insulin suppressed he-
patic glucose production much more effectively in WT mice (77.3 ±
12.9%) than hLRP1KOmice (26.4±5.6%, P b 0.005) indicative of hepatic
insulin resistance in hLRP1KO mice (Fig. S2d, right panel). Together,
these data demonstrate that liver-speciﬁc disruption of the Lrp1 gene
leads to latent hepatic insulin resistance, which can be unmasked by
HFD.
3.3. Hepatic LRP1 Deﬁciency Impairs Insulin Signaling in the Liver
To better understand the mechanisms involved in insulin resistance
in hLRP1KO mice, we investigated key insulin signaling molecules in
livers fromWTand hLRP1KOmice shortly after intraperitoneal injection
of insulin. Immunoblotting ofwhole liver extracts revealed that tyrosine
phosphorylation of IR, Serine473 phosphorylation of AKT, and Serine9
phosphorylation of GSK3βweremarkedly reduced in chow-fed and vir-
tually absent in HFD-fed hLRP1KO mice compared with similarly treat-
ed WT controls (Fig. 3a and 3b). Furthermore, whereas interaction
between insulin and IR normally inhibits gluconeogenesis, liver extracts
fromHFD-fed hLRP1KOmice showed a signiﬁcant increase in glucose 6-
phosphatase (G6pc) mRNA expression, a known gluconeogenic gene
Fig. 1. Hepatic LRP1 deﬁciency promotes diet-Induced obesity. (a) Western blotting for LRP1 expression in tissue extracts prepared from brain, liver, skeletal muscle and white adipose
tissue of WT and hLRP1KO mice. β-actin was used as loading control. (b) Body weight of age-matched male WT and hLRP1KO littermate mice that were fed chow diet or HFD for
16 weeks starting at 8 weeks of age. (n = 8–10 for each group, *P b 0.05; **P b 0.01 comparing hLRP1KO+HFD vs. WT+HFD). (c) Body weight and composition in 24-week-old WT
and hLRP1KO mice after 16 weeks of chow diet or HFD (n = 6–10 per group, **P b 0.01).
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of the gluconeogenesis pathway, phosphoenolpyruvate carboxykinase
1(Pck1), suggesting that G6pc and Pck1 are differentially regulated, as
has been described (Muse et al., 2004). In light of this emerging picture
of diet-induced insulin resistance, we wondered if there were also
systemic manifestations of insulin resistance. Immunoblotting and
immunohistochemistry of adipose tissue from hLRP1KO mice revealed
inhibition of insulin-mediated AKT phosphorylation and adipocyte hy-
pertrophy (Fig. S3, a, b and c). This is consistent with previous reports
of increased plasma glucose levels leading to secondary adipocyte
insulin-resistance. There were no corresponding differences in skeletal
muscle (Fig. S3d). Together, these data suggest that hLRP1 deﬁciency
leads to diet-induced hepatic and secondary adipocyte insulin resistance.
3.4. Hepatic LRP1 Deﬁciency Aggravates Palmitate-induced Insulin Resis-
tance in Primary Hepatocytes
To verify the effect of HFD and hLRP1 deﬁciency on insulin resis-
tance, primary hepatocytes from hLRP1KO and WT mice were treated
with insulin (100 nM) after pre-incubation with either BSA or the satu-
rated fatty acid palmitate. Consistent with in vivo results, we found a
signiﬁcant decrease in both phospho-IR and phospho-AKT in LRP1KO
hepatocytes compared to WT hepatocytes under both BSA and palmi-
tate treatment conditions (Fig. 4a and 4b).
To gain further insights into diet-induced insulin resistance in the
context of hLRP1 deﬁciency, we investigated insulin-induced transloca-
tion of IR, LRP1 andGLUT2 in primary hepatocytes. Since receptor trans-
location is activated within a very short time frame, we ﬁrst performed
surface biotinylation at serial time points, which showed that receptor
translocationwas initiated starting at 2min after treatmentwith insulin
(Fig. S4). Therefore, we chose 2 min for our future surface biotinylation
studies in vitro. As shown in Fig. 4c and 4d, in WT hepatocytes, insulin
stimulates translocation of LRP1 to the plasma membrane, but this is
inhibited by palmitate, suggesting that HFD alone can inhibit insulin-
induced translocation of LRP1. Compared to WT hepatocytes, LRP1KO
hepatocytes had decreased expression of surface IR (sIR), both at base-
line (0.46± 0.09 vs. 1 ± 0.09, P b 0.05) and after stimulation with insu-
lin (0.22 ± 0.16 vs. 0.5 ± 0.11). Treatment with palmitate diminished
surface IR expression inWT cells, but LRP1KO cells still had lower IR ex-
pression at the plasma membrane. Importantly, however, insulinstimulated the internalization of IR to a similar extent in both WT and
LRP1KO hepatocytes under BSA and palmitate-treated conditions. This
suggests that LRP1 is necessary for efﬁcient surface IR expression at
the plasma membrane, but not for IR internalization in response to
insulin.
In WT hepatocytes, insulin increased GLUT2 translocation in the
presence of lipid-free BSA. In the presence of palmitate, surface GLUT2
expressionwas even higher, andwas unresponsive to stimulation by in-
sulin. However, GLUT2 translocation in LRP1KO hepatocytes did not re-
spond to insulin either in the presence of BSA or palmitate. These
ﬁndings suggest a model where diet-induced insulin-resistance in the
hepatic LRP1 knockout is caused by attenuated surface expression of
IR and impaired GLUT2 translocation, but insulin-dependent internali-
zation of IR is unaffected.
Since the HFD consisted of 62% unsaturated fatty acids (~33% oleic,
~29% linoleic), we also examined whether these unsaturated fatty acid
affected receptor translocation in vitro. Unlike plamitate, neither oleic
nor linoic acids impaired insulin-stimulated LRP1 translocation in WT
hepatocytes. However, both oleic and linoic acids had effects similar to
that of palmitate on insulin-induced IR and GLUT2 translocation
(Fig. S5 and S6). These results suggest that saturated and unsaturated
fatty acids may differentially regulate receptor trafﬁcking in
hepatocytes.
3.5. Hepatic LRP1 Deﬁciency Leads to Diet-induced Dyslipidemia
Since hLRP1 is an essential regulator of lipoprotein metabolism,
we next investigated the effect of hepatic LRP1 deﬁciency on plasma
lipid levels in chow- and HFD-fed mice. As shown by Fig. 5a, on chow
diet, compared withWTmice, hLRP1KOmice had a 2-fold increase in
plasma TGs (185.4 ± 17.08 vs. 91.88 ± 7.66, P b 0.01), but on HFD,
TGs were decreased by 37.5% (86.4 ± 2.91 vs. 138.2 ± 8.42,
P b 0.01). FPLC lipoprotein analysis showed that this difference in
plasma TG concentration was reﬂected by a corresponding decrease
of VLDL levels (Fig. 5c). In terms of total cholesterol, on chow diet,
hLRP1KOmice had signiﬁcantly lower total plasma cholesterol levels
(100.68 ± 3.75 vs. 123.09 ± 5.66, P b 0.01), as would be expected
(Rohlmann et al., 1998), but this difference was abolished in mice
on a HFD. FPLC lipoprotein analysis showed that cholesterol content
in the HDL fractions in chow-fed hLRP1KO mice was signiﬁcantly
Fig. 2. LRP1 ablation aggravates diet-Induced insulin resistance. WT and hLRP1KO mice were maintained on chow diet or HFD for 16 weeks. (a) Fasting blood glucose and insulin levels
(n = 9–17 for each group, *P b 0.05, **P b 0.01, mean ± SEM). (b) Glucose tolerance test. Blood glucose was measured at the indicated time points after oral administration of glucose
(1 g/kg body weight). Area under the curve is quantiﬁed in the right panel (n = 9–11 for each group, *P b 0.05, **P b 0.01, mean ± SEM). AU, arbitrary unit. (c) Insulin tolerance test.
Plasma glucose levels after intraperitoneal injection of insulin (1 IU/kg body weight), expressed as a percentage of basal glucose levels. Area under the curve is quantiﬁed in the right
panel (n = 5–8 for each group, *P b 0.05, **P b 0.01, mean ± SEM). AU, arbitrary unit. (d) Pyruvate tolerance test. Plasma glucose levels after intraperitoneal injection of pyruvate
(1 g/kg body weight). (n = 6–9 for each group, *P b 0.05, **P b 0.01, mean ± SEM). AU, arbitrary unit.
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in cholesterol content of the HDL fraction in hLRP1KO and WT mice
maintained on a HFD (Fig. 5c). Finally, chow-fed hLRP1KO mice ex-
hibited signiﬁcantly higher levels of circulating NEFA (1.76 ± 0.09
vs. 1.37 ± 0.09, P b 0.01). After HFD feeding, hLRP1KO mice still
had increased NEFA levels compared to WT, but to a lesser extent
(1.02 ± 0.03 vs. 0.91 ± 0.03, P b 0.05).We then compared plasma apolipoprotein levels inWT and LRP1KO
mice. Although LRP1 deﬁciency had no effect on plasma apoAI levels or
distribution, apoB48 concentrations were markedly increased, with a
shift toward smaller sizes of VLDL/LDL-containing fractions in
hLRP1KO mice compared to WT mice on both chow and HFD (Fig. 5,
b, c and d). On the other hand, apoE and apoB100 levels were signiﬁ-
cantly lower in hLRP1KO mice relative to controls when fed the chow
Fig. 3.Hepatic LRP1 deﬁciency impairs insulin signaling in liver.WT and hLRP1KOmiceweremaintained on chowdiet or HFD for 16weeks. (a) After overnight fast, micewere pre-treated
with insulin (1 IU/kg, intraperitoneally), then sacriﬁced after 5 min. Total liver extracts were assayed for phosphorylation of IR, AKT and GSK3β, total IR, AKT and GSK3β expression by
Western blot. Calnexin was used as loading control. (b) Densitometric quantiﬁcation of the Western blot data (n = 4–5 for each group, *P b 0.05, **P b 0.01, mean ± SEM). (c) mRNA
was extracted from the liver and subjected to quantitative PCR to assess expression of genes associated with insulin signaling, glucose transport and gluconeogenesis (n = 5 for each
group, **P b 0.01, mean ± SEM).
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altered lipid and apolipoprotein proﬁle in hLRP1KOmice, we nextmea-
sured VLDL-TG secretion and plasma apoB levels in WT and hLRP1KO
mice by injecting tyloxapol to inhibit lipoprotein lipase activities. As
shown in Fig. 6a and 6b, HFD in hLRP1KO mice resulted in impaired
TG secretion. On the chow diet, the VLDL-TG secretion rate was 32.5%
higher in hLRP1-KO mice than that in WT mice (7.29 ± 0.28 vs. 5.5 ±
0.31, P b 0.01). However, after HFD feeding, VLDL-TG secretion was
25.1% lower in hLRP1-KO mice when compared to WT mice (4.56 ±
0.29 vs. 6.1 ± 0.48, P b 0.05), and 37.4% lower when compared toFig. 4. LRP1 deﬁciency reduces insulin signaling and GLUT2 translocation in primary hepatocy
albumin-bound palmitate or 0.5% BSA for 24 h, followed by the treatment of 100 nM insulin
and AKT. Calnexin was used as loading control. (b) Densitometric quantiﬁcation of the Wes
experiments (*P b 0.05, **P b 0.01, mean ± SEM). (c) Representative Western blots for surfac
translocation from three independent experiments (*P b 0.05, **P b 0.01, mean ± SEM).baseline conditions (chow diet) (4.56 ± 0.29 vs. 7.29 ± 0.28,
P b 0.01). In response to tyloxapol administration,WT apoB48 levels in-
creased to a level comparable to those in hLRP1KO mice on chow diet,
and on HFD, apoB48 levels in WT and hLRP1KO mice were indistin-
guishable (Fig. 6c and 6d). In contrast to apoB48, no changes in plasma
apoB100 levels following tyloxapol treatment were observed in chow-
fed or HFD-fed mice. Collectively, this variation in VLDL-TG secretion
was not correlated with alterations of plasma apoB48 levels between
WT and hLRP1KO mice, and enhanced plasma apoB48 in hLRP1KO
mice mostly resulted from delayed clearance of plasma apoB48tes. Primary hepatocytes fromWT and hLRP1KO mice were pre-incubated with 0.25 mM
for 2 min. (a) Representative Western blots for phosphorylated IR and AKT and total IR
tern blot data. The results are representative of those obtained from three independent
e biotinylated and total LRP1, IR, GLUT2. (d) Quantitative analysis of LRP1, IR, and GLUT2
Fig. 5. Hepatic LRP1 deﬁciency leads to diet-Induced dyslipidemia. WT and hLRP1KO mice were maintained on 16 weeks of chow diet or HFD. Plasma was collected after overnight fast.
(a) Plasma triglyceride, cholesterol and NEFA levels (n= 11–17 for each group, data aremean± SEM, *P b 0.05; **P b 0.01). (b) RepresentativeWestern blot (left panel) and quantitative
analysis (right panel) of plasma apolipoprotein levels (n = 5 for each group, data are mean± SEM, ⁎⁎P b 0.01). (c) Pooled plasma from 5mice from each group was analyzed by FPLC for
lipoprotein cholesterol (left) and triglyceride (right) content. (d) Equal aliquots (0.3mL) from three consecutive FPLC fractionswere pooled forWestern blot analysis of apoB100, apoB48,
apoE and apoAI levels in the different fractions.
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the established role of LRP1 as a chylomicron remnant receptor.
3.6. Hepatic LRP1 Deﬁciency Promotes HFD-induced Hepatosteatosis
We next examined the pathophysiological consequences of abnor-
mal lipoprotein metabolism in hLRP1KOmice. Morphological examina-
tion and Oil Red O staining of liver sections revealed a signiﬁcant
accumulation of lipid droplets in HFD-fed hLRP1KO mice compared to
HFD-fedWTmice (Fig. 7a). This was reﬂected in a 33.1% increase in he-
patic TG concentration (34.67 ± 0.64 vs. 26.05 ± 0.7, P b 0.01) and
slightly higher (3.52 ± 0.54 vs. 3 ± 0.14, although not signiﬁcantly)
cholesterol content in hLRP1KO mice compared to WT mice on HFD
(Fig. 7b). Although hLRP1KO mice showed a 45.5% higher hepatic
NEFA content than WT mice after chow-feeding (0.024 ± 0.003 vs.
0.016 ± 0.002, P b 0.01), no difference of NEFA levels was detected in
mice on HFD. Quantitative RT-PCR of RNA extracted from livers of WT
and hLRP1KOmice on chow diet and HFD did not reveal any signiﬁcant
changes in the expression of inﬂammatory markers (Fig. S7). However,plasma levels of aspartate aminotransferase (AST) and alanine amino-
transferase (ALT), were signiﬁcantly higher in HFD-fed hLRP1KO mice
(Fig. 7d). Theseﬁndings are consistentwith liver injury secondary to ex-
cess intrahepatic lipid accumulation, suggesting that hLRP1KOmice de-
velop non-alcoholic hepatic steatosis after prolonged HFD. To gain
insights into the molecular mechanisms underlying the hepatic
steatosis associated with LRP1 deﬁciency in the liver, we analyzed
genes involved in hepatic TG metabolism. As shown in Fig. 7c, the ex-
pression of most lipogenic genes, including those encoding fatty acid
synthase (Fas), acetyl-CoA carboxylase (Acc1) and diacylglycerol acyl-
transferase (Dgat1 and Dgat2), as well as the expression of hepatic
genes relevant to lipid uptake (Cd36) and VLDL secretion (microsomal
triglyceride transfer protein or Mtp), was similar between WT and
hLRP1KO mice on chow or HFD. However, the expression of stearyl
CoA desaturase 1 (Scd1) and glycerol-3-phosphate dehydrogenase
(Gpd1) was signiﬁcantly increased in both chow and HFD-fed hLRP1KO
mice compared to WTmice. In addition, the expression of transcription
factors involved hepatic lipogenesis, peroxisome proliferator-activated
receptor gamma coactivator 1-alpha (Ppargc1a) and sterol regulatory
Fig. 6.HFD impairs hepatic VLDL-Triglyceride secretion inhLRP1KOmice.WT and hLRP1KOmiceweremaintained on chowdiet orHFD for 16weeks. After 6 h of fasting,micewere treated
with an injection of tyloxapol. (a) PlasmaVLDL-TG levels at the indicated time points after injection of tyloxapol (n=5–7 for each group). (b) The rate of appearance of VLDL-TG in plasma
was calculated from the slope of the graph in (a) (Data are mean± SEM. *P b 0.05, **P b 0.01). (c)Western blot analysis of plasma apoB48 and apoB100 at the indicated time points after
tyloxapol injection. (d) Quantitative analysis of plasma apoB48 and apoB100 from 3 independent Western blots (*P b 0.05, **P b 0.01, mean ± SEM).
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whereas the expression of acetyl-CoA oxidase (Aco1), an oxidoreduc-
tase involved in fatty acid metabolism, was signiﬁcantly reduced in
HFD-fed hLRP1KOmice. No change in the expression ofMLX interacting
protein-like (Chrebp), liver nuclear receptor subfamily 1 (Lxra), peroxi-
some proliferator-activated receptor alpha (Ppara) and peroxisome
proliferator-activated receptor gamma (Pparg) was observed (Fig. S8).
Together, the changes in gene expression proﬁle suggest that LRP1 deﬁ-
ciency, combined with an excess of fatty acids, results in a pathological
shift of hepatic fatty acid metabolism from an oxidative to a synthetic
state.
In summary, our data demonstrate that hepatic LRP1 deﬁciency
causes a latent insulin-resistance, due to disrupted trafﬁcking of IR
andGLUT2,which is unmasked byHFD. The resultingdyslipidemia is as-
sociatedwith impaired hepatic TG secretion and a shift in fatty acidme-
tabolism towards fatty acid synthesis, leading to increased intrahepatic
lipid accumulation and ultimately liver injury associated with hepatic
steatosis.
4. Discussion
Our present studies in hLRP1KO mice show that hepatic inactiva-
tion of LRP1 primarily impairs insulin signal transduction by reducing
surface IR expression and suppressing GLUT2 translocation to plasma
membrane under normal physiological conditions. On a HFD, hLRPKO
mice develop severe insulin resistance and obesity. As a consequence
of nearly complete loss of hepatic insulin action, hLRP1KOmice develop
dyslipidemia secondary to increased lipogenesis, reduced fatty acid ox-
idation and reduced VLDL secretion. Collectively, our current results
demonstrate that hepatic LRP1 is a key regulator of insulin signalingand lipid homeostasis, two mechanisms that contribute to Metabolic
Syndrome.
A growing body of evidence has shown that excess dietary fat intake
impairs insulin action and leads to selective insulin resistance in the
liver (Perry et al., 2014; Riccardi et al., 2004) where LRP1 is abundantly
expressed and participates in lipoprotein metabolism (Rohlmann et al.,
1998). However, the physiological impact of hepatic LRP1 in selective
insulin resistance has remained elusive, thus prompting us to investi-
gate the relationship between LRP1 and hepatic insulin resistance. Al-
though no any obvious phenotype of insulin resistance was observed
in chow-fed hLRP1KO mice, our hyperinsulinemic-euglycemic clamp
studies indicate that targeted deletion of LRP1 is the primary cause of
hepatic insulin resistance, indicating that hepatic LRP1 is a critical deter-
minant of insulin sensitivity and hepatic insulin signal transduction.
When hLRP1KO mice were challenged with an HFD, they developed
whole-body insulin resistance characterized by hyperinsulinemia,
mild fasting hyperglycemia and glucose intolerance. Accordingly, LRP1
deﬁcient livers fail to respond to hyperinsulinemia, as evidenced by in-
complete suppression of hepatic gluconeogenic genes and impaired
insulin-induced phosphorylation of IR, AKT and GSK3β. These ﬁndings
are consistent with the general consensus that enhanced gluconeogen-
esis, secondary to impaired insulin action in hepatocytes, is a leading
cause of fasting hyperglycemia in Metabolic Syndrome. The blunted ac-
tivation of Akt and its downstream effector GSK3β in response to insulin
can be attributed to decreased expression of surface IR. Our ﬁndings in
primary hepatocytes are consistent with in vitro results demonstrating
that insulin stimulates the translocation of intracellular LRP1 to theplas-
ma membrane in different cell types (Descamps et al., 1993; Laatsch
et al., 2009; Liu et al., 2015), a process that is accompanied by the
rapid internalization of surface IR. Strikingly, however, insulin-induced
Fig. 7. Hepatic deletion of LRP1 accelerates the development of diet-induced fatty liver. (a) Representative Oil Red O staining (upper panel) and haematoxylin & eosin staining (lower
panel) of liver fromWT and hLRP1KO mice on chow diet or HFD for 16 weeks. Scale bar = 100 μm. (b) Lipids were extracted from the liver of WT and hLRP1KO mice maintained on
chow diet and HFD. Hepatic TG, total cholesterol and NEFA content were determined (n = 5 for each group, **P b 0.01, mean ± SEM). (c) Expression of key genes involved in fatty
acid metabolism and lipogenesis was evaluated by real-time PCR of reverse transcribed cDNA extracted from the livers of WT and hLRP1KO mice (n = 5 for each group, *P b 0.05,
**P b 0.01, mean ± SEM). (d) Plasma ALT and AST concentrations from WT and hLRP1KO mice after 16 weeks of chow diet or HFD (n = 5–8 for each group, *P b 0.05, **P b 0.01,
mean ± SEM).
143Y. Ding et al. / EBioMedicine 7 (2016) 135–145translocation of LRP1 is markedly attenuated in the presence of the free
fatty acid palmitate. An association between LRP1 and IR is supported by
a recent proteomic analysis demonstrating the presence of a LRP1-
insulin receptor complex that functions in a co-internalization process
for insulin clearance in mouse liver (Bilodeau et al., 2010). Unexpected-
ly, although LRP1KO hepatocytes have decreased surface IR expression,
there was no change in insulin-stimulated internalization of IR, indicat-
ing that unlike in primary neurons (Liu et al., 2015), there may be other
mechanisms that govern IR internalization in the liver. Because insulin-
activated IR internalization remains intact in LRP1KO hepatocytes, in-
teraction of IR with LRP1 primarily controls IR expression at the plasma
membrane, but not its endocytosis.
LRP1may also act as an essential scaffoldingmolecule that facilitates
insulin-stimulated tyrosine phosphorylation of IR and downstream sig-
naling cascades. Loss of LRP1 translocation, or attenuated LRP1 translo-
cation in the presence of palmitate, would then result in impaired
hepatic insulin signaling.
In addition to regulating surface IR expression, LRP1 is a key compo-
nent of GSVs that regulate GLUT4 trafﬁcking (Jedrychowski et al., 2010).
Depletion of LRP1 from 3T3-L1 adipocytes signiﬁcantly reduced GLUT4
expression and decreased insulin-stimulated 2-[3H]deoxyglucose up-
take. However, GLUT2, but not GLUT4, is the major glucose transporter
in healthyhepatocytes. The similarities betweenmolecularmechanisms
regulating GLUT2 and GLUT4 translocation remain unclear. In the liver,
GLUT2 regulates both glucose uptake and output (Burcelin et al., 2000;
Thorens et al., 1990). Our in vitro data show that LRP1 deﬁciency does
not affect GLUT2 protein expression. However, insulin-stimulated
GLUT2 translocation from the cytosol to the plasmamembrane is signif-
icantly attenuated in LRP1 deﬁcient hepatocytes. In view of previous
studies showing that loss of hepatic GLUT2 in mice suppresses hepaticglucose uptake but not secretion, leading to progressive development
of glucose intolerance (Guillam et al., 1998; Seyer et al., 2013), our
novel ﬁndings indicate that defective translocation of GLUT2, at least
in part, accounts for impaired glucosemetabolism and the development
of hyperglycemia in hLRP1KO mice.
Both patients with Metabolic Syndrome and animal models of insu-
lin resistance exhibit dyslipidemia characterized by increased plasma
concentrations of VLDL-TG, low levels of HDL-cholesterol, aswell as rel-
atively normal levels of LDL cholesterol, but increased numbers of small,
dense LDL particles (Choi and Ginsberg, 2011). Our data show that plas-
ma TG levels in hLRP1KO mice are increased on chow diet, but de-
creased after HFD. These ﬁndings match the altered hepatic VLDL-TG
secretion, but independent of the secretion of both apoB100 and
apoB48. Although plasma cholesterol levels in hLRP1KO mice are re-
duced on chow diet, they rise to a level similar to those observed in
WT mice on HFD. These ﬁndings are not paralleled by an increase of
VLDL-TG. The uncoupling of cholesterol and TG secretion is also ob-
served in liver-speciﬁc deﬁciency of IR (LIRKO)mice, wherein increased
secretion of apoB and cholesterol is accompanied by decreased TG se-
cretion (Biddinger et al., 2008). This highlights an important role of TG
mobilization for VLDL assembly in the regulation of VLDL secretion.
The dyslipidemia in the hLRP1KO mouse model also includes in-
creased levels of circulating NEFA, which itself is a strong predictor for
insulin resistance. Although plasma NEFA levels in hLRP1KO mice are
signiﬁcantly higher than inWTmice, theywere reduced after HFD feed-
ing. Under fasting conditions, the plasma NEFA pool mainly originates
from two sources: i) adipose tissue TG lipolyzed by adipose TG lipase
(ATGL) and hormone sensitive lipase (HSL) in adipose tissue; ii) and
plasma TG lipolyzed by lipoprotein lipase (LPL). Previous studies have
demonstrated that LRP1 directly interacts with LPL in vitro and hepatic
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(Espirito Santo et al., 20S04; Herz and Strickland, 2001). Additionally,
in the adipose-speciﬁc LRP1 knockout mice, cell-surface LPL is elevated
signiﬁcantly in both WAT and brown adipose tissue (Hofmann et al.,
2007). Therefore, it remains to be determined whether higher levels
of adipose tissue lipolysis by lipases contribute to elevated plasma
NEFA levels in hLRP1KO mice.
Along with dyslipidemia, hepatic LRP1 deﬁciency results in hepatic
TG accumulation and severe hepatic steatosis following HFD feeding.
Hepatic steatosis occurs when there is an imbalance between lipid in-
ﬂux (lipid delivery and de novo lipogenesis) and lipid efﬂux (lipid oxi-
dation and export via VLDL) (Lee et al., 2011). Our results indicate
that LRP1 deﬁciency is associated with lipogenesis through enhanced
expression of hepatic Scd1 and Gpd1. This is aggravated by HFD treat-
ment, which leads to the activation of hepatic Srebf1c expression. Con-
currently, the expression of genes involved in fatty acid oxidation was
signiﬁcantly reduced. Although the expression of most genes involved
in de novo lipogenesis and FFA uptake are not affected by the absence
of LRP1, inhibition or knockout of SCD1 in the liver is sufﬁcient to pro-
tect mice from diet-induced obesity and hepatic steatosis (Jiang et al.,
2005; Ntambi et al., 2002). Without any modiﬁcation of the expression
of Mtp, it is possible that augmented availability of NEFAs and subse-
quently more NEFA delivery to the liver could be a cause of increased
VLDL-TG secretion in chow-fed hLRP1KO mice. However, in HFD-fed
hLRP1KO mice with hyperinsulinemia, which itself has been shown to
suppress hepatic VLDL secretion (Lee et al., 2011), excess circulating
NEFA may overwhelm the capacity of the liver to unload excess TG as
VLDL, leading to hepatic TG accumulation and ultimately hepatic
steatosis.
Glucose intolerance and impaired insulin signaling in adipose tissue
was detected only after several weeks of HFD, but not chow diet, in
hLRP1-KO mice. This indicates that the HFD may progressively worsen
the LRP1 deﬁciency-induced pure hepatic insulin resistance and further
reduce insulin clearance, leading to peripheral hyperinsulinemia and in-
sulin resistance in adipose tissues. Similarly, the hyperinsulinemia in
LIRKO mice also leads to insulin resistance in fat and muscle in the ab-
sence of hypertriglyceridemia (Brown and Goldstein, 2008). In contrast
to the LIRKO model, LRP1 deﬁciency induces a partial functional IR de-
fect, which predisposes the mice to diet-induced insulin resistance
and hepatic steatosis rather than directly triggering the development
of insulin resistance, independent of a dietary stimulus.
In summary, our ﬁndings highlight the common causality of dyslip-
idemia, insulin resistance, and hepatic steatosis inMetabolic Syndrome.
They further emphasize the physiological relevance of LRP1 for main-
taining insulin sensitivity and preventing hepatic steatosis and thus un-
derscore the central role of LRP1 as an integrator of energy homeostasis
and lipoprotein metabolism.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.04.002.
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